No Data
No Data
Cryofocus Medtech Converts Over 29 Million Unlisted Shares to H Shares
Kangfeng Biotechnology-B (06922.HK) completes the full circulation of H shares.
Grandall September 5th | Kanglong Biosciences-B (06922.HK) announced that approximately 29.342 million shares of non-listed shares have been converted to H shares on September 5, 2024, and the conversion of H shares will be listed on the Hong Kong Stock Exchange at 9 am on September 6, 2024. Participating shareholders must complete the applicable domestic arrangements before they can proceed with the H share trade.
Kangfeng Biotechnology-B (06922) released its interim results, with a shareholder's net loss of 52.171 million yuan, a year-on-year increase of 202.2%.
According to the finance and economics news app, Kang Yong Biotechnology-B (06922) released its performance for the six months ending on June 30, 2024, during which the group achieved revenue ...
Express News | Cryofocus Medtech Shanghai H1 Revenue RMB 19.5 Million
Express News | Cryofocus Medtech Shanghai H1 Gross Margin 78.5%
CRYOFOCUS-B: INTERIM RESULTS ANNOUNCEMENTFOR THE SIX MONTHS ENDED JUNE 30, 2024
No Data
No Data